Loading...
•
Sep 30, 2020
BeiGene Q3 2020 Earnings Report
BeiGene's product revenue increased due to sales of tislelizumab in China and BRUKINSA in the United States and China.
Key Takeaways
BeiGene reported an increase in product revenue driven by sales of tislelizumab in China and BRUKINSA in the United States and China. The company is focused on expanding its pipeline and commercial opportunities.
Total product revenue reached $91.08 million, a 81.6% increase compared to the same period last year.
Sales of tislelizumab in China contributed $49.94 million.
Sales of BRUKINSA in China and the United States amounted to $15.66 million.
The company is progressing with clinical trials and regulatory submissions for its drug candidates.
BeiGene
BeiGene
BeiGene Revenue by Segment
Revenue by Segment
Brukinsa Revenue
CapyFin.com Forward Guidance
BeiGene anticipates key clinical readouts and potential expanded commercial opportunities for its products through approvals in additional indications and geographic markets.
Positive Outlook
- Key clinical readouts expected in the remainder of 2020 and 2021.
- Potential expanded commercial opportunities for products.
- Possible approvals in additional indications and geographic markets.
- Growing commercial-stage portfolio in China to up to 12 products.
- Advancement of pipeline assets, including BGB-11417, BGB-A445, BGB-10188, and BGB-15025.
Challenges Ahead
- COVID-19 pandemic continues to have a negative impact on operations.
- Delays in clinical trial recruitment and data readouts due to COVID-19.
- Uncertainty regarding the future impact of the pandemic in China and the United States.
- Potential delays in regulatory interactions, inspections, and filings.
- Amgen collaboration clinical trials in China are currently delayed.